

## Recovery Gains Traction Amid Margin Protection Initiatives

Est. Vs. Actual for Q4FY26: Revenue – **BEAT** ; EBITDA – **MISS**; PAT – **BEAT**

### Changes in Estimates post Q4FY26

FY27E/FY28E: Revenue: -3%/0%; EBITDA: -5%/0%; PAT: -3%/0%

### Recommendation Rationale

- Resilient Volume-led Growth Driven by Domestic Business:** Dabur India reported consolidated revenue growth of 7.3% YoY in Q4FY26, supported by healthy volume expansion of 6%, reflecting steady underlying demand trends. The domestic FMCG business remained the key growth driver, registering 9.5% YoY growth, while the international business delivered relatively moderate growth of 2.5% in INR terms amid geopolitical disruptions in West Asia. Rural markets continued to outperform urban regions during the quarter, reinforcing the company's strong rural franchise. Within the portfolio, the Health Care segment remained a standout performer, delivering robust growth of 17% YoY.
- Margins and Profitability:** Dabur India reported a 12 bps YoY expansion in EBITDA margin to 15.2%, aided by improvement in gross margins, while PAT grew 15.1% YoY. To offset elevated inflationary pressures, the company has undertaken calibrated pricing measures, including ~4% price hikes and selective grammage reductions in smaller packs to protect affordability and profitability. Management also highlighted continued monitoring of crude-linked raw material and packaging costs, which remain volatile amid inflationary pressures and geopolitical uncertainties.
- Strategic Levers and Outlook:** Consumption levels have remained steady, bolstered by both direct and indirect tax benefits. The company is also positioned to reap further advantages with GST-related benefits expected to materialise in Q1FY27. Management aims to protect margins, which is a higher priority than aggressive market share expansion. While they remain watchful of the volatile international landscape and are prepared to calibrate advertising spends based on margin performance, the overall outlook remains focused on disciplined cost optimisation and passing inflationary impacts through to the consumer, if needed.

### Sector Outlook: Positive

**Company Outlook & Guidance:** Dabur's long-term growth trajectory remains intact, and hence, we maintain our **BUY** rating on the stock; however, the company remains cautious regarding ongoing crises in West Asia, and hence, we cut our FY27 estimates.

**Current Valuation:** 42x Mar'28 EPS (Earlier Valuation: 46x Dec'27 EPS)

**Current TP:** Rs 550/share (Earlier TP: Rs 595/share)

**Recommendation:** With an upside potential of 17% from the CMP, we maintain our **BUY** rating on the stock

**Financial Performance:** The company's consolidated revenue grew by 7.3% YoY to Rs 3,038 Cr, with the India business growing by 9.5% YoY, while the international business expanded by 2.5% YoY in INR terms. EBITDA margins improved by 12 bps YoY to 15.2%, led by Gross margin expansion of 164 bps. The company reported a PAT of Rs 369 Cr, up 15% YoY.

### Key Financials (Consolidated)

(Rs Cr)	Q4FY26	QoQ (%)	YoY (%)	Axis Est.	Variance (%)
Net Sales	3,038	-14.6	7.3	2,989	2%
EBITDA	462	-37.1	8.2	468	-1%
EBITDA Margins (%)	15.2	-543 bps	12 bps	15.7	-46 bps
Net Profit	369	-34.2	15.1	357	3%
EPS (Rs)	2.1	-34.2	15.1	2.0	3.2

Source: Company, Axis Securities Research

(CMP as of 7<sup>th</sup> May 2026)

CMP (Rs)	470
Upside /Downside (%)	17%
High/Low (Rs)	576/ 401
Market cap (Cr)	83,372
Avg. daily vol.(6m) Shrs. '000	1974
No. of shares (Cr)	177

### Shareholding (%)

	Sep-25	Dec-25	Mar-26
Promoter	66.2	66.2	66.3
FII's	10.9	10.1	10.0
MFs / UTI	8.0	7.3	7.1
Banks / FI's	0.0	0.1	0.1
Others	14.8	16.4	16.6


### Financial & Valuations

Y/E Mar (Rs Cr)	FY26	FY27E	FY28E
Net Sales	13,193	14,061	15,621
EBITDA	2,452	2,632	3,028
Net Profit	1,895	2,048	2,351
EPS (Rs.)	10.7	11.6	13.3
PER (x)	43.6	40.5	35.3
EV/EBITDA (x)	32.4	29.6	25.3
P/BV (x)	7.3	6.7	6.2
ROE (%)	16.7	16.6	17.5

### Change in Estimates (%)

Y/E Mar	FY27E	FY28E
Sales	-3%	0%
EBITDA	-5%	0%
PAT	-3%	0%

### Relative Performance



Source: Ace Equity, Axis Securities

### Results Gallery

[Q3FY26](#)

[Q2FY26](#)

[Q1FY26](#)

[Q4FY25](#)

### Suhanee Shome

Research Associate

email: suhanee.shome@axissecurities.in

## Outlook & Recommendation

Dabur experienced a noteworthy increase in rural demand in the past few quarters. Looking ahead, the company's strategic emphasis on expanding rural distribution networks, combined with anticipated improvements in rural demand driven by factors such as a normal monsoon, moderation of core inflation, heightened government expenditure, the GST cut in food items and personal care, and the upcoming festive season, is expected to provide significant support to its performance in the forthcoming quarters. We continue to believe in Dabur's long-term growth story and remain constructive on its prospects, particularly appreciating: (1) The management's focus on strong execution—market share gains, go-to-market initiatives, deepening rural penetration; (2) Strong management bandwidth; (3) Continued investments in the brands, distribution infrastructure, and innovations and (4) Capital infusion. These factors underpin our confidence in the company's long-term growth potential. **We therefore maintain our BUY rating and value the company at 42x Mar'28E EPS, with a TP of Rs 550/share, implying 17% upside from the CMP.**

## Segmental Performance

- Home & Personal Care:** The HPC segment delivered a robust 17% YoY growth, driven by strong performance across its entire portfolio. Hair Care was a standout, with hair oils growing at 28% and gaining 154 bps in volume market share through double-digit growth in both coconut and perfume oils, while shampoos grew by 20%. Homecare surged by 24%, led by Odomos at 48% growth (88 bps market share gain) and Odonil at 20% growth (243 bps market share gain), particularly fueled by the success of gel pockets. Additionally, Skincare grew 12.5% behind the Gulabari brand, and Oral Care rose by 7%, with its Herbal segment growing at twice the rate of non-herbal products.
- Healthcare:** The Healthcare segment recorded a 2.2% YoY increase, characterised by significant market share gains in core categories. Hajmola grew by 12.7%, expanding its market share by 233 bps, while Isabgul saw an exceptional growth of over 53%. Honey grew by 24%, gaining 150 bps in market share, and Honitus delivered a strong 36% growth driven by its cough syrup and Hotsips range, benefiting from its differentiated non-drowsy positioning. Although Dabur Glucose sales were hampered by unseasonal rains in Mar'26, it continued to gain market share, while Dabur Lal Tail maintained double-digit growth supported by targeted media spending and interventions.
- Foods and Beverages:** The F&B segment grew by 3.2% YoY, marked by a sharp sequential recovery in Beverages, where Real Activ juices grew by 26% and gained 280 bps in market share. While the core Nectar business was impacted by unseasonal rains, newer low-sugar varieties helped the brand secure a 250 bps market share gain. Notably, Coconut Water saw 100% growth on a small base—disrupting the carbonated drinks market with an exit ARR of Rs 150 Cr—and the Badshah brand grew by 12.5%. Management expects the overall F&B segment to reach double-digit growth, especially if severe summer conditions drive increased consumption.

## International Business

The International business is facing a "triple impact" of supply chain disruptions, high inflation, and falling demand, particularly in West Asia, as Asian expatriates leave the region. To manage these hurdles, the company is rerouting supply chains at a higher cost and raising prices to offset the higher costs. Although actual sales volumes are declining, the segment is still expected to post double-digit growth figures, largely due to the impact of currency depreciation.

## Key Risks to Our Estimates and TP

- War-led inflation, demand slowdown, and advertisement spends.

## Change in Estimates

	Old		New		% Change	
	FY27E	FY28E	FY27E	FY28E	FY27E	FY28E
Revenue	14,437	15,698	14,061	15,621	-3%	0%
EBITDA	2,759	3,014	2,632	3,028	-5%	0%
PAT	2,116	2,341	2,048	2,351	-3%	0%
EPS	12	13.3	11.6	13.3	-3%	0%

Source: Company, Axis Securities Research

**Q4FY26 Results Review**

Rs Cr	Q4FY25	Q3FY26	Axis Sec Est.	Q4FY26	YoY Growth (%)	QoQ Growth (%)	Axis Sec Var
<b>Net Sales</b>	<b>2,830</b>	<b>3,559</b>	<b>2,989</b>	<b>3,038</b>	<b>7.3</b>	<b>(14.6)</b>	<b>1.6</b>
<b>Gross Profits</b>	<b>1,321</b>	<b>1,722</b>	<b>1,390</b>	<b>1,468</b>	<b>11.1</b>	<b>(14.7)</b>	<b>5.6</b>
<b>Gross Margin (%)</b>	<b>46.7</b>	<b>48.4</b>	<b>46.5</b>	<b>48.3</b>	<b>164 bps</b>	<b>-6 bps</b>	<b>183 bps</b>
Staff costs	294	352	306	338	14.9	(3.9)	10.5
Ad spends	176	238	183	215	21.6	(9.9)	16.9
Other operating expenses	423	398	432	453	7.1	14.0	5.0
<b>EBITDA</b>	<b>427</b>	<b>734</b>	<b>468</b>	<b>462</b>	<b>8.2</b>	<b>(37.1)</b>	<b>(1.4)</b>
<b>EBITDA margin (%)</b>	<b>15.1</b>	<b>20.6</b>	<b>15.7</b>	<b>15.2</b>	<b>12 bps</b>	<b>-543 bps</b>	<b>-46 bps</b>
Depreciation	117	117	118	122	4.6	4.3	3.8
EBIT	310	617	350	340	9.6	(45.0)	(3.1)
Other Income	141	141	145	175	24.0	24.5	20.8
Interest Cost	39	31	31	40	1.8	28.4	27.2
<b>PBT</b>	<b>412</b>	<b>726</b>	<b>464</b>	<b>475</b>	<b>15.2</b>	<b>(34.7)</b>	<b>2.3</b>
Tax rate (%)	24.1	21.7	23.0	23.5	-55 bps	185 bps	53 bps
<b>PAT</b>	<b>320</b>	<b>560</b>	<b>357</b>	<b>369</b>	<b>15.1</b>	<b>(34.2)</b>	<b>3.2</b>
<b>EPS</b>	<b>1.8</b>	<b>3.2</b>	<b>2.0</b>	<b>2.1</b>	<b>15.1</b>	<b>(34.2)</b>	<b>3.2</b>

Source: Company, Axis Securities Research

## Financials (Consolidated)

### Profit & Loss

(Rs Cr)

Y/E Mar	FY25	FY26	FY27E	FY28E
<b>Net sales</b>	<b>12,563</b>	<b>13,193</b>	<b>14,061</b>	<b>15,621</b>
Growth, %	1.3	5.0	6.6	11.1
Raw material expenses	(6,535)	(6,824)	(7,233)	(7,993)
Employee expenses	(1,291)	(1,376)	(1,444)	(1,574)
Other Operating Expenses	(2,421)	(2,541)	(2,751)	(3,026)
<b>EBITDA (Core)</b>	<b>2,316</b>	<b>2,452</b>	<b>2,632</b>	<b>3,028</b>
Growth, %	(3.5)	5.8	7.4	15.0
Margin, %	18.4	18.6	18.7	19.4
Depreciation	(446)	(469)	(476)	(532)
<b>EBIT</b>	<b>1,871</b>	<b>1,983</b>	<b>2,156</b>	<b>2,496</b>
Growth, %	(6.5)	6.0	8.7	15.7
Margin, %	14.9	15.0	15.3	16.0
Interest paid	(164)	(145)	(156)	(169)
Other Income	550	600	660	726
Non-recurring Items	-	(15)	-	-
<b>Pre-tax profit</b>	<b>2,258</b>	<b>2,420</b>	<b>2,660</b>	<b>3,053</b>
Tax provided	(517)	(552)	(612)	(702)
<b>Profit after tax</b>	<b>1,740</b>	<b>1,869</b>	<b>2,048</b>	<b>2,351</b>
<b>Net Profit</b>	<b>1,768</b>	<b>1,895</b>	<b>2,048</b>	<b>2,351</b>
Growth, %	(4.1)	8.1	7.2	14.8
<b>Net Profit (adjusted)</b>	<b>1,768</b>	<b>1,895</b>	<b>2,048</b>	<b>2,351</b>
Unadj. shares (Cr)	177	177	177	177

Source: Company, Axis Securities Research

### Balance Sheet

(Rs Cr)

As of 31 <sup>st</sup> Mar	FY25	FY26	FY27E	FY28E
Cash & bank	578	562	1,644	3,081
Marketable securities at cost	2,088	4,638	4,638	4,638
Debtors	889	715	763	847
Inventory	2,300	2,322	2,474	2,749
Loans & advances	-	-	-	-
<b>Total current assets</b>	<b>6,535</b>	<b>8,928</b>	<b>10,211</b>	<b>12,006</b>
Investments	5,380	4,352	4,352	4,352
Gross fixed assets	6,756	6,756	6,956	7,156
Less: Depreciation	(2,766)	(2,766)	(3,242)	(3,775)
Add: Capital WIP	169	137	137	137
<b>Net fixed assets</b>	<b>4,159</b>	<b>4,127</b>	<b>3,851</b>	<b>3,519</b>
<b>Total assets</b>	<b>16,232</b>	<b>17,573</b>	<b>18,579</b>	<b>20,043</b>
Current liabilities	4,318	5,239	5,434	5,783
Provisions	71	172	79	79
<b>Total current liabilities</b>	<b>4,390</b>	<b>5,411</b>	<b>5,512</b>	<b>5,862</b>
Non-current liabilities	632	359	359	359
<b>Total liabilities</b>	<b>5,022</b>	<b>5,770</b>	<b>5,872</b>	<b>6,221</b>
Paid-up capital	177	177	177	177
Reserves & surplus	10,623	11,242	12,147	13,261
Shareholders' equity	11,210	11,803	12,708	13,822
<b>Total equity &amp; liabilities</b>	<b>16,232</b>	<b>17,573</b>	<b>18,579</b>	<b>20,043</b>

Source: Company, Axis Securities Research

**Cash Flow**
**(Rs Cr)**

Y/E Mar	FY25	FY26	FY27E	FY28E
Pre-tax profit	2,258	2,420	2,660	3,053
Depreciation	446	469	476	532
Chg in working capital	(168)	1,066	(5)	(10)
Total tax paid	(478)	(540)	(612)	(702)
Other operating activities	-	-	-	-
<b>Cash flow from operating activities</b>	<b>2,057</b>	<b>3,415</b>	<b>2,519</b>	<b>2,873</b>
Capital expenditure	(557)	(437)	(200)	(200)
Chg in investments	(114)	1,029	-	-
Chg in marketable securities	(421)	(2,550)	-	-
Other investing activities	-	-	-	-
<b>Cash flow from investing activities</b>	<b>(1,092)</b>	<b>(1,961)</b>	<b>(200)</b>	<b>(200)</b>
Free cash flow	966	1,454	2,319	2,673
Equity raised/(repaid)	184	619	(619)	0
Debt raised/(repaid)	(220)	(289)	-	-
Dividend (incl. tax)	(1,418)	(1,325)	(1,329)	(1,236)
Other financing activities	-	-	-	-
<b>Cash flow from financing activities</b>	<b>(1,453)</b>	<b>(995)</b>	<b>(1,948)</b>	<b>(1,236)</b>
Net chg in cash	(488)	459	371	1,436


Source: Company, Axis Securities Research

**Ratio Analysis**
**(%)**

	FY25	FY26	FY27E	FY28E
<b>Per Share data</b>				
EPS (Rs)	10.0	10.7	11.6	13.3
Growth, %	(4.1)	8.1	7.6	14.8
Book NAV/share (Rs)	61.0	64.4	69.8	76.1
FDEPS (Rs)	10.0	10.8	11.6	13.3
CEPS (Rs)	12.5	13.5	14.3	16.3
CFPS (Rs)	9.8	12.4	10.5	12.2
DPS (Rs)	8.0	8.0	7.0	7.0
<b>Return ratios</b>				
Return on assets (%)	12.1	11.9	12.2	13.0
Return on equity (%)	16.4	16.7	16.6	17.5
Return on capital employed (%)	16.5	16.7	17.4	18.4
<b>Turnover ratios</b>				
Asset turnover (x)	3.0	3.4	3.9	4.8
Sales/Total assets (x)	0.8	0.8	0.8	0.8
Sales/Net FA (x)	3.1	3.2	3.5	4.2
Working capital/Sales (x)	(0.0)	(0.1)	(0.1)	(0.1)
Fixed capital/Sales (x)	-	-	-	-
Working capital days	(13.0)	(44.4)	(39.1)	(34.9)
<b>Liquidity ratios</b>				
Current ratio (x)	1.5	1.7	1.9	2.1
Quick ratio (x)	1.0	1.2	1.4	1.6
Interest cover (x)	11.4	13.6	13.8	14.8
Total debt/Equity (%)	0.1	0.1	0.1	0.1
Net debt/Equity (%)	(0.2)	(0.3)	(0.0)	(0.1)
<b>Valuation</b>				
PER (x)	47.1	43.6	40.5	35.3
Price/Book (x)	7.7	7.3	6.7	6.2
EV/Net sales (x)	6.5	6.0	5.5	4.9
EV/EBITDA (x)	35.2	32.4	29.6	25.3
EV/EBIT (x)	43.6	40.0	36.2	30.7

Source: Company, Axis Securities Research

## Dabur India Price Chart and Recommendation History



Date	Reco	TP	Research
31-Oct-24	BUY	600	Result Update
31-Jan-25	BUY	610	Result Update
08-May-25	HOLD	610	Result Update
01-Aug-25	HOLD	560	Result Update
04-Sep-25	BUY	630	Company Update
31-Oct-25	BUY	590	Result Update
30-Jan-26	BUY	595	Result Update
08-May-26	BUY	550	Result Update

Source: Axis Securities Research

## Disclaimer

Axis Direct is the brand under Axis Securities Limited, which is a 100% subsidiary of Axis Bank Limited. Axis Bank Ltd. is a listed public company and one of India's largest private sector banks, and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on [www.axisbank.com](http://www.axisbank.com).

Axis Securities Limited is registered as a

- Stock Broker, Depository Participant, Portfolio Manager, Investment Adviser and Research Analyst with the Securities and Exchange Board of India
- Corporate Agent with Insurance Regulatory and Development Authority of India
- Point of Presence with Pension Fund Regulatory and Development Authority
- Distributor for Mutual Funds with AMFI

Registration Details:

SEBI Single Reg. No.- NSE, BSE, MSEI, MCX & NCDEX – INZ000161633 | SEBI Depository Participant Reg. No. IN-DP-403-2019 | Portfolio Manager Reg. No.- INP000000654 | Investment Advisor Reg No. INA000000615 | SEBI-Research Analyst Reg. No. INH000000297 | IRDA Corporate Agent (Composite) Reg. No. CA0073| PFRDA – POP Reg. No. POP387122023 | Mutual Fund Distributor ARN- 64610.

Compliance Officer Details: Name – Mr Rajiv Kejriwal, Tel No. – 022-68555574, Email id – [compliance.officer@axisdirect.in](mailto:compliance.officer@axisdirect.in);

Registered Office Address – Axis Securities Limited, Unit No.002, Building- A, Agastya Corporate Park, Piramal Realty, Kamani Junction, Kurla (W), Mumbai – 400070.

Administrative office address: Axis Securities Limited, Aurum Q Parc, Q2 Building, Unit No. 1001, 10th Floor, Level – 6, Plot No. 4/1 TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai, Pin Code – 400710.

In case of any grievances, please call us at 022-40508080 or write to us at [helpdesk@axisdirect.in](mailto:helpdesk@axisdirect.in).

We hereby declare that our activities have neither been suspended nor have we defaulted with any stock exchange authority with whom we are registered in the last five years. However, SEBI, Exchanges, Clearing Corporations and Depositories, etc. have conducted the routine inspection and based on their observations have issued advice/warning/show cause notices/deficiency letters/ or levied penalty or imposed charges for certain deviations observed in inspections or in the normal course of business, as a Stock Broker/Depository Participant/Portfolio Manager. We have not been debarred from doing business by any Stock Exchange/SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point in time.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

By referring to any particular sector, Axis Securities does not provide any promise or assurance of a favourable view for a particular industry or sector or business group in any manner.

Registration granted by SEBI, membership of RAASB (in case of RA's) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors. Our research should not be considered as an advertisement or advice, professional or otherwise. This research report and its respective content by Axis Securities made available on this page or otherwise do not constitute an offer to sell or purchase or subscribe for any securities or solicitation of any investments or investment services for the residents of Canada and/or the USA or any jurisdiction where such an offer or solicitation would be illegal.

Subject company(ies) may have been clients during the twelve months preceding the date of distribution of the research report. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment of its original date of publication by ASL and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

The information and opinions in this report have been prepared by Axis Securities and are subject to change without notice. The report and information contained herein are strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Axis Securities. The report must not be used as a singular basis for any investment decision. The views herein are of a general nature and do not consider the risk appetite, investment objective or the particular circumstances of an individual investor. The investor is requested to take into consideration all the risk factors, including their financial condition, suitability to risk return profile and the like and take professional advice before investing.

While we would endeavour to update the information herein on a reasonable basis, Axis Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Axis Securities from doing so. Non-rated securities indicate that the rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Axis Securities policies, in circumstances where Axis Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained in good faith from public sources and sources believed to be reliable, but no independent verification has been made, nor is its accuracy or completeness guaranteed. This report and information herein are solely for informational purposes and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Axis Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and/or tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and the needs of the specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks.

The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Axis Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see the Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Axis Securities or its associates might have managed or co-managed a public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. Axis Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. Axis Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking, or brokerage services from the companies mentioned in the report in the past twelve months. Axis Securities encourages independence in research report preparation and strives to minimise conflict in the preparation of research reports. Axis Securities or its associates, or its analysts, did not receive any compensation or other benefits from the companies mentioned in the report or a third party in connection with the preparation of the research report. Accordingly, neither Axis Securities nor Research Analysts and/or their relatives have any material conflict of interest at the time of publication of this report. Please note that Axis Securities has a proprietary trading desk. This desk maintains an arm's length distance from the Research team, and all its activities are segregated from Research activities. The proprietary desk operates independently, potentially leading to investment decisions that may deviate from research views.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Research Analyst may have served as an officer, director or employee of the subject company(ies). Axis Securities or Research Analysts, or their relatives, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report. Since associates of Axis Securities and Axis Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one per cent or more or other material conflicts of interest in various companies, including the subject company/companies mentioned in this report. Axis Securities may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report. Certain transactions-including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centre on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender/borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Axis Securities may have proprietary long/short positions in the above-mentioned scrip(s) and therefore may be considered as interested. This should not be construed as an invitation or solicitation to do business with Axis Securities. Axis Securities is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independently of the PCG research, and accordingly, PMS may have positions contrary to the PCG research recommendation.

This research report is issued in India by Axis Securities Limited in accordance with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014. It is intended solely for persons residing in India. The report is not directed at or intended for distribution to, or use by, any person or entity resident in the United States of America, Canada, or in any jurisdiction where such distribution, publication, availability, or use would be contrary to applicable securities laws, including the U.S. Securities Exchange Act of 1934, regulations of the U.S. Securities and Exchange Commission (SEC), and regulations of the Canadian Securities Administrators (CSA).

#### RATING SCALE: Definitions of ratings

<b>Ratings</b>	<b>Expected absolute returns over 12 – 18 months</b>
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward-looking estimates for the stock, but we refrain from assigning a valuation and recommendation.
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events.
NO STANCE	We do not have any forward-looking estimates, valuations or recommendations for the stock.

Note: Returns stated in the rating scale are our internal benchmark.